ESMO: Combination immunotherapy in second/third line extends mesothelioma survival to 15 months

Combination immunotherapy as second or third line treatment extends overall survival to at least 15 months in patients with pleural malignant mesothelioma, according to late-breaking results from the MAPS2 trial presented at the ESMO 2017 Congress in...

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vNDQWh
via IFTTT